This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease (NCT04808908), a na phase 1 study. The primary outcome is Safety (Adverse Event Rate).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04808908 |
| Phase | Phase 1 |
| Condition | Hiv, HIV Infections, AIDS |
| Allocation | Not applicable (single group) |
| Design model | Single Group |
| Masking | None (open label) |
| Enrollment | 10 |
| Arms in the primary outcome | n/a |
| Lead sponsor | University of Minnesota |
| Results posted | Yes |
2. Clinical Question
Population
People with HIV receiving antiretroviral treatment. The registry record does not report the detailed eligibility criteria or the characteristics of the enrolled participants.
Intervention
N-803, a biological intervention. The registry describes all participants as receiving N-803 treatment.
Comparator
There is no comparator group. The study is listed as single-group, with no allocation to different treatments.
Primary question
What is the safety profile of N-803, measured as the number of adverse events per participant during 6 months?
The study rationale focuses on B cell follicles, where part of the HIV reservoir is described as residing. The registry summary proposes that N-803 could increase CD8 T cells in those follicles and further reduce the frequency of cells with an inducible provirus. Those statements describe the study's rationale and hypothesis; they are not results.
The listed secondary outcome is the frequency of CD8+ T cells in follicles. The registry record does not report a result for that outcome. Because all participants receive N-803 and no comparison group is listed, the design cannot directly estimate how outcomes would differ under N-803 versus a control condition. The main question that can be addressed from the posted safety counts is descriptive: which adverse-event categories were recorded among participants in the N-803 group.
3. Trial Design
NCT04808908 is listed as a Phase 1 study sponsored by the University of Minnesota. Its title is “Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease.” The registry lists the design as single-group, with no allocation to treatment groups and no masking. The record describes all participants as receiving N-803.
Enrollment is listed as 10. The study started on 2021-04-01, reached primary completion on 2022-07-18, and has a completed status in the registry. The brief summary calls the study phase 1b, while the phase field lists Phase 1. These design details describe the record; they do not establish how many participants completed every study procedure or contributed data to each outcome.
The primary outcome is safety, defined as the number of adverse events per participant over 6 months, including all adverse events regardless of severity. The registry specifies a mean and standard deviation as the summary measures. A secondary outcome is the frequency of CD8+ T cells in follicles. The registry record does not report outcome analyses for either measure.
This is not a randomized comparison: there is no control arm against which to estimate a treatment contrast. The single-group design can describe observations among participants receiving N-803, but it does not separate treatment-associated changes from changes that might have occurred over time or for other reasons. The registry record does not report a detailed protocol, study visit schedule, or account of participant follow-up beyond the stated outcome timeframe.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | N-803 |
|---|---|
| STARTED | 10 |
| COMPLETED | 10 |
| NOT COMPLETED | 0 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | N-803 |
|---|---|---|
| Participants analysed | 10 | |
| Age, Categorical: <=18 years | Participants | 0 |
| Age, Categorical: Between 18 and 65 years | Participants | 10 |
| Age, Categorical: >=65 years | Participants | 0 |
| Sex: Female, Male: Female | Participants | 0 |
| Sex: Female, Male: Male | Participants | 10 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 |
| Race (NIH/OMB): Asian | Participants | 0 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 |
| Race (NIH/OMB): Black or African American | Participants | 2 |
| Race (NIH/OMB): White | Participants | 8 |
| Race (NIH/OMB): More than one race | Participants | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 |
6. Primary Endpoint
The registry lists the primary outcome as Safety (Adverse Event Rate), measured over 6 months.
| Element | Registry entry |
|---|---|
| Result type | Mean |
| Measure of spread | Standard Deviation |
| Unit | adverse events per participant |
| Endpoint classification | Event-Rate Endpoint |
The primary endpoint is safety, expressed as the number of adverse events per participant during 6 months. The description says that all adverse events are included, regardless of severity. The registry specifies the mean and standard deviation for this outcome, so the intended summary is the average event count per participant together with a measure of how much counts vary between participants.
As a general statistical explanation, a mean gives a compact description of the overall event burden in a group. It does not show whether events were spread evenly across participants or concentrated among a few. The standard deviation describes variation in individual counts around the mean, but it does not describe the types, timing, or clinical seriousness of events. Those details require separate reporting.
The record also classifies the outcome as an event rate per unit of exposure. Its endpoint description, however, states the unit as adverse events per participant and does not report a more detailed exposure-time calculation. The registry record does not report the observed mean or standard deviation for the primary endpoint, so the planned measure can be described but its realized value cannot be interpreted from the posted record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry lists a completed single-group study with enrollment of 10 and N-803 as the intervention. Its stated primary outcome is the number of adverse events per participant over 6 months. The posted record does not report the mean, standard deviation, confidence interval, or other analysis for that primary outcome. Consequently, the overall event burden and its precision cannot be assessed from the primary endpoint as described.
The adverse-event summary lists 10 participants at risk for serious adverse events and 0 affected. For other adverse events, it lists 10 at risk and 10 affected. Deaths are listed as 0. These are descriptive counts in the registry summary. They do not supply the event count per participant, the distribution of event counts, the timing of events, or a comparison with another group. The record does not list serious adverse-event terms among the top serious terms.
The secondary outcome concerns the frequency of CD8+ T cells in follicles. The registry record does not report an outcome analysis for it. The proposed reduction in cells with an inducible provirus appears in the study rationale, but the record does not identify a posted result for that hypothesis. Neither the rationale nor the completed status can substitute for an outcome estimate.
With no comparator group, the posted counts cannot establish whether the observed events were more or less frequent than they would have been without N-803. Likewise, a single-group observation cannot distinguish treatment effects from background events, changes over time, or other influences. This is a design limitation on causal interpretation, not a claim about the direction of any effect.
The record lists 0 analyses. It does not report a statistical analysis of the primary or secondary outcome, inferential estimates, or uncertainty intervals. Thus the safety counts can be read as the posted descriptive summary, while claims about the magnitude, precision, or cause of outcome changes are not supported by an analysis reported in the registry record.
9. Statistical Methods Explained
The registry describes a single-group study and specifies a mean and standard deviation for its primary safety outcome. The record does not report the analysis methods used to produce outcome estimates. The explanations below are general statistical context, not a description of analyses confirmed in the registry.
What does a mean event count describe?
For a count outcome, the mean is the average number of events per participant in the group being summarized. It condenses all observed counts into one value. That makes it useful as a broad description of event burden, but it can obscure the pattern of the counts. Participants might have similar counts, or a small number might account for many events. The mean alone cannot distinguish those patterns.
The standard deviation describes the spread of individual counts around the mean. It is not the range of observed values and does not indicate how many participants had a particular number of events. A mean and standard deviation are most informative when accompanied by clear definitions of the counted events and a description of the underlying distribution. The registry record does not report the primary endpoint's observed mean or standard deviation.
Why can count data need special care?
As a general matter, event counts are nonnegative and may be unevenly distributed. Some participants may have no events while others experience multiple events. When variation is greater than a simple model expects, statisticians describe the data as over-dispersed. Ignoring over-dispersion can make standard errors too small and confidence intervals too narrow. A model for counts may account for this feature, but the registry record does not report a model choice or diagnostics for the primary outcome.
Exposure also matters when counting events. Participants followed for different lengths of time may have different opportunities to experience an event. A rate model can account for exposure time, whereas a simple per-participant count does not necessarily do so. The registry's stated timeframe is 6 months and its outcome unit is adverse events per participant; further details about exposure handling are not reported in the registry record.
What would an uncertainty interval add?
In general, a confidence interval expresses the uncertainty around an estimate under the assumptions of the analysis. It can help readers distinguish a relatively precise estimate from one compatible with a broad range of values. It does not guarantee that the true value lies within the particular interval, and it does not address biases caused by study design or measurement. No confidence interval for the primary endpoint is reported in the registry record.
A standard error and a confidence interval are different from the standard deviation. The standard deviation describes variation among participant-level observations; the standard error describes uncertainty in an estimated group quantity. A report of the mean and standard deviation alone would therefore not provide the same information as an interval around the mean. Neither measure, in isolation, would resolve the absence of a comparator group.
What can a single-group design estimate?
A single-group study can describe outcomes observed among the participants receiving the intervention. A comparison of outcomes before and after treatment, if collected and analyzed, could describe change over time, but such a comparison would not by itself establish that treatment caused the change. The registry record does not report a before-and-after analysis. With no control group, there is no randomized between-group estimate of the intervention's effect.
The posted serious and other adverse-event counts are descriptive summaries. They are not an estimate of excess risk relative to an untreated or differently treated group. The listed affected counts also do not give the full distribution of event counts per participant, which is the primary outcome's stated unit. A reader should not infer a mean event rate from the affected counts.
How should planning illustrations be read?
The registry's sample-size assumptions describe a planning illustration rather than the design of this single-group study. The stated framework assumes a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect to detect expressed as a fraction of an observed effect. Such assumptions describe a hypothetical planning exercise; they are not a report of the actual study design or observed power. Sample sizes from a planning exercise are not observed results. The registry record does not report the study's own sample-size justification.
The record does not report the analysis population, treatment of missing observations, handling of repeated events, or a prespecified model for the event outcome. Without those details and the outcome estimates, readers cannot reproduce an analysis or judge its sensitivity to alternative assumptions. These are limits on what can be inferred from the registry record, rather than evidence that any particular statistical method was or was not used.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists a primary safety outcome and a secondary outcome concerning the frequency of CD8+ T cells in follicles. It also reports 2 outcome measures and 0 analyses. The record does not describe a multiplicity strategy, such as how interpretation would account for examining more than one outcome. Without reported analyses, it is not possible to determine whether or how multiplicity was addressed.
Missing-data methods are not reported in the registry record. It does not state how missing outcome measurements, incomplete follow-up, or participants without evaluable data were handled. The completed status and enrollment figure do not establish that every enrolled participant contributed information to each outcome, so completeness should not be assumed.
The record does not report a primary analysis population or explain whether all enrolled participants, participants who received treatment, or another defined group would be included in each analysis. It also does not report exclusions or the amount of outcome data available. These details affect the interpretation of both descriptive summaries and any inferential analysis.
No statistical analysis plan, model specification, or method for uncertainty estimation is reported in the registry record. The adverse-event summary gives counts for the N-803 group, but does not explain whether event ascertainment or follow-up differed across participants. As a result, the posted information supports only a limited descriptive reading of those counts; it does not permit an assessment of missing-data bias or multiplicity-adjusted inference.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| N-803 | 0 | 10 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| N-803 | 0 of 10 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| N-803 | 10 of 10 |
Most frequent non-serious adverse event terms
| Event term | Organ system | N-803 |
|---|---|---|
| Injection site erythema | General disorders | 10 of 10 |
| Myalgia | General disorders | 9 of 10 |
| Fatigue or malaise | General disorders | 8 of 10 |
| Headache | General disorders | 8 of 10 |
| pain | General disorders | 7 of 10 |
| lymphadenopathy | Blood and lymphatic system disorders | 6 of 10 |
| fever | General disorders | 5 of 10 |
| Injection site induration | General disorders | 4 of 10 |
The registry's adverse-event summary lists 10 participants at risk for serious adverse events, with 0 affected. For other adverse events, it lists 10 at risk and 10 affected. The listed number of deaths is 0. These figures should be read as the registry's group-level counts, not as the primary endpoint's mean number of adverse events per participant.
An affected count describes participants recorded as affected in that category; it does not tell how many events each affected participant experienced. The counts also do not show event timing, duration, recurrence, or the distribution of severity among other adverse events. The registry record does not list top serious-event terms. It does not report a comparison group, so these counts cannot describe an excess or reduction relative to another treatment or to no treatment.
The primary endpoint includes all adverse events regardless of severity, but its observed mean and standard deviation are not reported in the registry record. The serious-event counts therefore do not replace the missing summary of the primary endpoint. They are a limited safety description, not a complete account of the event-rate outcome.
12. What the Result Does, and Does Not, Mean
The posted record establishes that NCT04808908 was registered as a completed, single-group study of N-803 in antiretroviral-treated HIV disease, with safety as its primary outcome. The adverse-event summary lists serious-event and other-event affected counts, as well as deaths. These counts are descriptive observations for the N-803 group.
The record does not report the mean number of adverse events per participant, its standard deviation, or an uncertainty interval. It also does not report an analysis of the secondary CD8+ T-cell follicle outcome. The study hypothesis about follicular CD8 T cells and inducible provirus is a rationale for the investigation, not evidence that either outcome changed.
The absence of a comparator is central to interpretation. Even if a change or event count is observed in a treated group, a single-group record cannot show what would have happened to a comparable group without N-803. It therefore cannot isolate a treatment effect from background events, time trends, or other influences.
These limitations do not negate the value of descriptive safety information from an early-phase study. They define its scope: the registry record can communicate what its summary counts say, but it does not support a controlled treatment comparison or a precise estimate of the primary event-rate outcome. Conclusions about efficacy, causal effects, or the proposed biological changes are not reported in the registry record.
13. Why This Trial Matters Statistically
This study raises a statistical distinction between a biological hypothesis and the data needed to evaluate it. The rationale proposes changes in CD8 T cells in B cell follicles and in cells with an inducible provirus. The registry lists a safety endpoint and a secondary follicle outcome, but does not report analyses of those outcomes. Clear separation of hypothesis, endpoint, and result is essential when reading an early-phase record.
The single-group design also illustrates the difference between describing observations and estimating a treatment contrast. Counts among participants receiving N-803 can be reported descriptively. Without a comparator, they cannot show whether the intervention changed the outcome relative to an alternative. This matters especially when the clinical context includes background events and biological variation that may occur independently of treatment.
For safety, the listed affected counts do not by themselves describe the primary outcome's mean event burden or its variability. A complete statistical account would need the event-count summary and enough information about follow-up, event definitions, and missing observations to interpret it. Those elements are not reported in the registry record.
The record is therefore useful as an example of why registry status and a set of adverse-event counts are not substitutes for outcome estimates and their uncertainty. Statistical interpretation depends not only on which numbers are posted, but also on the design and the information needed to understand how those numbers were generated.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The single-group design is the main limitation for causal interpretation. All participants are described as receiving N-803, and no comparator group is listed. Any observed outcome could not be contrasted with an outcome under a control condition using this design information alone.
The registry record does not report the primary endpoint's observed mean or standard deviation, despite defining safety as adverse events per participant over 6 months. It also does not report a confidence interval or an analysis for the secondary frequency of CD8+ T cells in follicles. The summary's affected counts do not supply the event-count distribution needed to characterize the primary endpoint fully.
Detailed eligibility criteria, participant characteristics, outcome definitions beyond the brief descriptions, event ascertainment procedures, follow-up completeness, and missing-data handling are not reported in the registry record. The record does not report an analysis population or a statistical analysis plan. These omissions restrict assessment of representativeness, precision, and potential bias.
The record lists 0 analyses. Its completed status does not establish that every planned outcome was measured or analyzed, and enrollment does not establish complete follow-up. The registry also does not report a multiplicity approach or the study's own sample-size justification. These limitations are specific to interpreting the record and should not be replaced by assumptions about the protocol or analyses.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease — NCT04808908.
- Registry record last updated 2024-04-02; status last verified 2024-03.
- Results first posted 2024-04-02.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT04808908, sponsored by the University of Minnesota, is listed as a completed Phase 1, single-group study of N-803 in antiretroviral-treated HIV disease. Enrollment is 10. The study started on 2021-04-01 and reached primary completion on 2022-07-18.
The primary outcome is safety, defined as adverse events per participant over 6 months, with all severities included. A secondary outcome is the frequency of CD8+ T cells in follicles. The adverse-event summary lists 0 affected by serious events, 10 affected by other events, and 0 deaths. The registry record does not report an analysis of the primary or secondary outcome, the primary endpoint's mean and standard deviation, or a comparator group.